These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
448 related articles for article (PubMed ID: 34687488)
1. Clinicopathological features and resistance mechanisms in HIP1-ALK-rearranged lung cancer: A multicenter study. Kang J; Deng QM; Peng KC; Li P; Zhu BT; Wang P; Chu XP; Zhong WZ; Chen HJ; Wang WX; Chen HF; Rao CZ; Xu CW; Yang JJ Genes Chromosomes Cancer; 2022 Apr; 61(4):177-186. PubMed ID: 34687488 [TBL] [Abstract][Full Text] [Related]
2. HIP1-ALK, a novel ALK fusion variant that responds to crizotinib. Fang DD; Zhang B; Gu Q; Lira M; Xu Q; Sun H; Qian M; Sheng W; Ozeck M; Wang Z; Zhang C; Chen X; Chen KX; Li J; Chen SH; Christensen J; Mao M; Chan CC J Thorac Oncol; 2014 Mar; 9(3):285-94. PubMed ID: 24496003 [TBL] [Abstract][Full Text] [Related]
3. Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib. Ou SH; Klempner SJ; Greenbowe JR; Azada M; Schrock AB; Ali SM; Ross JS; Stephens PJ; Miller VA J Thorac Oncol; 2014 Dec; 9(12):1821-5. PubMed ID: 25393796 [TBL] [Abstract][Full Text] [Related]
4. Unique molecular features and clinical outcomes in young patients with non-small cell lung cancer harboring ALK fusion genes. Tian P; Liu Y; Zeng H; Tang Y; Lizaso A; Ye J; Shao L; Li Y J Cancer Res Clin Oncol; 2020 Apr; 146(4):935-944. PubMed ID: 31894386 [TBL] [Abstract][Full Text] [Related]
5. Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK-rearranged non-small-cell lung cancer. Song P; Zhang F; Li Y; Yang G; Li W; Ying J; Gao S Cancer Med; 2019 Apr; 8(4):1551-1557. PubMed ID: 30843662 [TBL] [Abstract][Full Text] [Related]
6. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing. Lin YT; Chiang CL; Hung JY; Lee MH; Su WC; Wu SY; Wei YF; Lee KY; Tseng YH; Su J; Chung HP; Lin CB; Ku WH; Chiang TS; Chiu CH; Shih JY Eur J Cancer; 2021 Oct; 156():1-11. PubMed ID: 34392186 [TBL] [Abstract][Full Text] [Related]
7. miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC. Lai Y; Kacal M; Kanony M; Stukan I; Jatta K; Kis L; Norberg E; Vakifahmetoglu-Norberg H; Lewensohn R; Hydbring P; Ekman S Biochem Biophys Res Commun; 2019 Apr; 511(2):260-265. PubMed ID: 30791979 [TBL] [Abstract][Full Text] [Related]
8. A rare KIF5B-ALK fusion variant in a lung adenocarcinoma patient who responded to crizotinib and acquired the ALK L1196M mutation after resistance: a case report. Zeng H; Liu Y; Wang W; Tang Y; Tian P; Li W Ann Palliat Med; 2021 Jul; 10(7):8352-8357. PubMed ID: 33832282 [TBL] [Abstract][Full Text] [Related]
9. Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in Pailler E; Faugeroux V; Oulhen M; Mezquita L; Laporte M; Honoré A; Lecluse Y; Queffelec P; NgoCamus M; Nicotra C; Remon J; Lacroix L; Planchard D; Friboulet L; Besse B; Farace F Clin Cancer Res; 2019 Nov; 25(22):6671-6682. PubMed ID: 31439588 [TBL] [Abstract][Full Text] [Related]
10. Genetic correlation of crizotinib efficacy and resistance in ALK- rearranged non-small-cell lung cancer. Liu C; Liu C; Liao J; Yin JC; Wu X; Zhao X; Sun S; Wang H; Hu Z; Zhang Y; Yu H; Shao Y; Wang J Lung Cancer; 2022 Sep; 171():18-25. PubMed ID: 35870258 [TBL] [Abstract][Full Text] [Related]
11. Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of Urbanska EM; Sørensen JB; Melchior LC; Costa JC; Santoni-Rugiu E Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32325863 [No Abstract] [Full Text] [Related]
12. Inflammation-related molecular signatures involved in the anticancer activities of brigatinib as well as the prognosis of EML4-ALK lung adenocarcinoma patient. Ge FJ; Dai XY; Qiu Y; Liu XN; Zeng CM; Xu XY; Chen YD; Zhu H; He QJ; Gai RH; Ma SL; Chen XQ; Yang B Acta Pharmacol Sin; 2024 Jun; 45(6):1252-1263. PubMed ID: 38360931 [TBL] [Abstract][Full Text] [Related]
13. Investigation on the prognostic impact of concurrent genomic alterations in crizotinib-treated EML4-ALK-rearranged advanced non-small cell lung cancer patients. Zheng J; Zhu Y; Sun K; Shen Q; Wang Y; Cao H; Lizaso A; Yu B; Lin J; Chen S; Zhou J; Zhou J Lung Cancer; 2020 Aug; 146():209-216. PubMed ID: 32563740 [TBL] [Abstract][Full Text] [Related]
14. Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer. Yu Y; Ou Q; Wu X; Bao H; Ding Y; Shao YW; Lu S Lung Cancer; 2019 Jan; 127():19-24. PubMed ID: 30642546 [TBL] [Abstract][Full Text] [Related]
15. Relevance of Detection of Mechanisms of Resistance to ALK Inhibitors in ALK-Rearranged NSCLC in Routine Practice. Jamme P; Descarpentries C; Gervais R; Dansin E; Wislez M; Grégoire V; Richard N; Baldacci S; Rabbe N; Kyheng M; Kherrouche Z; Escande F; Copin MC; Cortot AB Clin Lung Cancer; 2019 Jul; 20(4):297-304.e1. PubMed ID: 31147208 [TBL] [Abstract][Full Text] [Related]
16. De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers. Lucena-Araujo AR; Moran JP; VanderLaan PA; Dias-Santagata D; Folch E; Majid A; Kent MS; Gangadharan SP; Rangachari D; Huberman MS; Kobayashi SS; Costa DB Lung Cancer; 2016 Sep; 99():17-22. PubMed ID: 27565908 [TBL] [Abstract][Full Text] [Related]
17. Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer. Yamaguchi N; Lucena-Araujo AR; Nakayama S; de Figueiredo-Pontes LL; Gonzalez DA; Yasuda H; Kobayashi S; Costa DB Lung Cancer; 2014 Jan; 83(1):37-43. PubMed ID: 24199682 [TBL] [Abstract][Full Text] [Related]
18. Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer. Lin JJ; Zhu VW; Yoda S; Yeap BY; Schrock AB; Dagogo-Jack I; Jessop NA; Jiang GY; Le LP; Gowen K; Stephens PJ; Ross JS; Ali SM; Miller VA; Johnson ML; Lovly CM; Hata AN; Gainor JF; Iafrate AJ; Shaw AT; Ou SI J Clin Oncol; 2018 Apr; 36(12):1199-1206. PubMed ID: 29373100 [TBL] [Abstract][Full Text] [Related]
19. Distribution of ALK Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib. Su Y; Long X; Song Y; Chen P; Li S; Yang H; Wu P; Wang Y; Bing Z; Cao Z; Cao L; Wu Y; Zhang Z; Liu J; Li B; Xiang J; Ma K; Zhang T; Zhang L; Mao X; Liu H; Xing P; Liang N Target Oncol; 2019 Apr; 14(2):159-168. PubMed ID: 30895431 [TBL] [Abstract][Full Text] [Related]
20. ALK inhibitors in the treatment of advanced NSCLC. Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]